Introduction
============

The biologically active metabolite of vitamin D~3~, 1α,25-dihydroxyvitaminD~3~ \[1α,25(OH)~2~D~3~\], acts through an intracellular receptor \[vitamin D receptor (VDR)\] and has a main role in the regulation of calcium and phosphorus metabolism \[[@B1]\]. It also has several immunomodulatory actions such as its effect on the differentiation and proliferation of T lymphocytes, and the regulation of immunoglobulin production by B lymphocytes \[[@B2],[@B3],[@B4]\].1α,25(OH)~2~D~3~ may affect chondrocytic function, such as proteoglycan and collagen synthesis \[[@B5]\]; and animal studies have shown that the production of some matrix metalloproteinases (MMPs), namely interstitial collagenase (MMP-1), stromelysin (MMP-3) and 72-kDa gelatinase (MMP-2), may be upregulated in rat chondrocytes by administration of the metabolite \[[@B6]\]. Discoordinate regulation by vitamin D of MMP-1 and MMP-9 in human mononuclear phagocytes has also been reported \[[@B7]\]. Together these data have suggested that vitamin D can regulate MMP expression in tissues or pathologies where receptors for the hormone are expressed.

The kidney is recognized as the primary source of 1α,25(OH)~2~D~3~, producing the metabolite via 1-hydroxylation of 25-hydroxyvitamin D~3~-\[[@B1]\]. However, the local production of 1α,25(OH)~2~D~3~ within synovial fluids of arthritic joints, especially the macrophage component, has recently been indicated \[[@B8],[@B9]\]; and receptors for vitamin D have also been demonstrated in rheumatoid synovial tissues and at sites of cartilage erosion \[[@B10]\]. Such studies have demonstrated a local source of 1α,25(OH)~2~D~3~ within the rheumatoid joint, but its regulation and physiological functions at this site remain obscure.

MMPs are reputed to play a major role in cartilage breakdown in the rheumatoid joint and are produced locally by several cell types, but especially by synovial fibroblasts and articular chondrocytes \[[@B11],[@B12],[@B13],[@B14],[@B15],[@B16]\]. MMP production and release is microenvironmental in nature and is tightly regulated by several factors, including the proinflammatory cytokines tumour necrosis factor-α and interleukin (IL)-1β \[[@B17]\]. Because 1α,25(OH)~2~D~3~ has been shown to modulate the production of specific MMPs and is produced within the rheumatoid joint, the present study was designed to investigate the effects of 1α,25(OH)~2~D~3~ on MMP and prostaglandin E~2~ (PGE~2~) production by rheumatoid synovial fibroblasts (RSFs) and human articular chondrocytes (HACs), cell types known to express chondrolytic enzymes both *in vitro* and *in vivo*.

Methods
=======

Tissue samples
--------------

Samples of rheumatoid synovial tissue, cartilage and cartilage-pannus junction were obtained from arthroplasty procedures performed on patients with classic late-stage rheumatoid arthritis. Normal articular cartilage samples were obtained from lower limb amputations. Samples were fixed in Carnoy\'s fixative at 20°C for 2 h, embedded in paraffin wax and 5 μm sections cut. Tissue sections were dewaxed, rehydrated and examined for the presence of VDR.

Immunolocalization of vitamin D receptors
-----------------------------------------

Tissue sections were treated with 2N HCl at 37°C for 30 min, this being the antigen retrieval procedure recommended by the supplier of the primary antibody. Nonimmune rabbit serum at 10% (vol : vol) in TRIS-buffered saline was applied to the sections for 20 min at 20°C before incubation with the primary antibody. Rat monoclonal antibody to chick VDR (Biogenex, San Remo, USA), which is known to cross-react with human VDR, was applied to the sections for 2 h at 20°C after dilution 1 : 40 in TRIS-buffered saline. After 3 × 10 min washing in TRIS-buffered saline, biotinylated rabbit anti-rat immunoglobulin G (DAKO, Glostrup, Denmark) diluted 1 : 200 in TRIS-buffered saline was applied to the sections for 45 min at 20°C. After further washing in TRIS-buffered saline, alkaline phosphatase-conjugated ABC (Avidin-biotin complex system; DAKO) was applied to the sections for 45min at 20°C, diluted as instructed by the supplier. After further washing the alkaline phosphatase was developed using new fuchsin substrate to give a red colour. Sections were lightly counterstained using Harris\'s haematoxylin or toluidine blue. Non-immune rat immunoglobulin G was substituted for the primary antibody at similar concentrations on control tissue sections \[[@B10]\].

Cell cultures
-------------

Rheumatoid synovial tissue and human articular cartilage were enzymically digested to provide synovial fibroblast and chondrocyte cultures as previously described \[[@B18],[@B19]\]. Cells were grown in Dulbecco\'s Modified Eagle\'s Medium + 10% (vol : vol) foetal calf serum, harvested and seeded into 12-well culture dishes (Nunc, Gibco, UK) Triplicate wells of confluent cell cultures in Dulbecco\'s Modified Eagle\'s Medium + 2% foetal calf serum were treated with 1α,25(OH)~2~D~3~ (10^-8^ mol/l), IL-1β (0.05 ng/ml), or IL-1β + 1α,25(OH)~2~D~3~ (0.05 ng/ml and 10^-8^ mol/l, respectively) and incubated for 48 h at 37°C. The conditioned medium was collected and assayed for MMP-1, MMP-2, MMP-3 and MMP-9, and PGE~2~ using enzyme-linked immunosorbent assay (ELISA) methodology. Cell numbers per well were counted at the end of each experiment after 70% ethanol fixation and toluidine blue staining.

Enzyme linked immunosorbent assays
----------------------------------

ELISA methodology was used to determine protein levels of MMP-1 (collagenase 1), MMP-3 (stromelysin) and MMP-9 (gelatinase B) as previously described \[[@B20]\]. MMP-2 (Gelatinase A) was measured using ELISA kits purchased from The Binding Site (Birmingham, UK); and PGE~2~ was measured using an ELISA assay kit purchased from R & D Systems Europe, Ltd (Abingdon,UK).

All ELISA results were initially calculated in ng or pg protein/ml culture medium/10^6^ cells per 48 h. Three different cultures of both RSFs and HACs were examined, but the capacities of each cell type to produce the MMPs and PGE~2~ varied between the individual cultures. Therefore, the data from each culture was \'normalized\' relative to control values, and the data sets from the three cultures of each cell type were subsequently pooled. This provided an evaluation that showed qualitative similarities for the RSFs and HACs, but demonstrated differences in 1α,25(OH)~2~D~3~ responses by each of these two cell types.

Results
=======

Demonstration of the vitamin D receptor in rheumatoid tissues *in vivo*
-----------------------------------------------------------------------

Specimens of rheumatoid synovial tissue (*n* = 18) immunostained for VDR were shown to have variable distributions of the receptor. All specimens showed some positive staining, but this could be less than 5% or as much as 70% of the total cell population. Different cell types within the synovial specimens were shown to express the receptor, including macrophages, endothelial cells, lymphocytes and fibroblastic cells, but no regular pattern was observed. Cells with fibroblastic morphology immunostained for VDR are shown in Figure [1a](#F1){ref-type="fig"}. Chondrocytes within articular cartilage from rheumatoid joints also expressed the receptor in six out of 10 specimens (Fig. [1b](#F1){ref-type="fig"}), this being a much higher frequency compared with the one in 10 specimens of normal articular cartilage from nonarthritic joints (data not shown). VDR-positive cells were also observed in association with some cartilage--pannus junctions, described here as the rheumatoid lesion (Fig. [1c](#F1){ref-type="fig"}).

Effects of 1α,25-dihydroxyvitamin D~3~ on matrix metalloproteinase production by rheumatoid synovial fibroblasts
----------------------------------------------------------------------------------------------------------------

1α,25(OH)~2~D~3~ alone had no effect on basal MMP production by RSFs in monolayer culture, but the simultaneous addition of 1α,25(OH)~2~D~3~ with IL-1β reduced the expected stimulation of MMP-1, MMP-3 and MMP-9 by up to 50% (Fig. [2](#F2){ref-type="fig"}: *P* = 0.096, 0.009 and 0.01, for IL-1β versus IL-1β + 1α,25(OH)~2~D~3~ for MMP-1, MMP-3 and MMP-9, respectively, by Student\'s *t*-test). MMP-2 production was not affected by either IL-1β or IL-1β + 1α,25(OH)~2~D~3~ (data not shown), an observation that is in accord with the constitutive nature of MMP-2 expression \[[@B21]\].

Effects of 1α,25-dihydroxyvitamin D~3~ on matrix metalloproteinase production by human articular chondrocytes
-------------------------------------------------------------------------------------------------------------

In contrast to the data for RSFs, 1α,25(OH)~2~D~3~ had a slight stimulatory effect on basal production of MMP-1 and MMP-3 by monolayer cultures of HAC (Fig. [3](#F3){ref-type="fig"}: *P* = 0.098 and 0.002, for control versus 1α,25(OH)~2~D~3~, for MMP-1 and MMP-3, respectively, by Student\'s *t*-test). When stimulated with IL-1β MMP-1 and MMP-3 production was increased, and although simultaneous addition of 1α,25(OH)~2~D~3~ had no effect on the stimulation of the MMP-1 enzyme, MMP-3 production was further enhanced (Fig [3b](#F3){ref-type="fig"}: *P* = 0.008, by Students *t*-test). MMP-9 and MMP-2 were not produced in measurable quantities by these HAC cultures, either with or without IL-1β stimulation.

Effects of 1α,25-dihydroxyvitamin D~3~ on prostaglandin E~2~ production by rheumatoid synovial fibroblasts and human articular chondrocytes
-------------------------------------------------------------------------------------------------------------------------------------------

PGE~2~ production by RSFs was unaffected by the addition of 1α,25(OH)~2~D~3~ alone. Treatment of RSFs with IL-1β upregulated the production of PGE~2~, but the addition of 1α,25(OH)~2~D~3~ together with IL-1β reduced the expected stimulation of PGE~2~ almost to control values (Fig. [4a](#F1){ref-type="fig"}:*P* = 0.014, for IL-1β versus IL-1β + 1α,25(OH)~2~D~3~, by Student\'s *t*-test).

Treatment of HACs with IL-1β also increased the production of PGE~2~, but in contrast to the effects noted for RSFs this IL-1-stimulation of PGE~2~ was not affected by the concomitant addition of 1α,25(OH)~2~D~3~ (Fig. [4b](#F4){ref-type="fig"}).

To examine the possibility that 1α,25(OH)~2~D~3~ might obscure or interact with the IL-1β receptor of RSFs the latter were pretreated with 1α,25(OH)~2~D~3~ before incubation with IL-1β. Figure [4c](#F4){ref-type="fig"} shows that a 1-h preincubation with 1α,25(OH)~2~D~3~followed by IL-1β was not significantly different from the two factors added together, but preincubation with 1α,25(OH)~2~D~3~ for 16 h suppressed the expected increase in PGE~2~ production to control values. This effect was noted even when the 1α,25(OH)~2~D~3~ was removed after the 16 h and IL-1β then added alone (Fig.4c, data column F). Thus, rather than directly interfering with the IL-1β receptor, it appears that 1α,25(OH)~2~D~3~ reduces the capacity of the RSFs to elaborate PGE~2~ (and probably the MMPs shown in Fig. [2](#F2){ref-type="fig"}) after IL-1β induction.

![Immunolocalization of the vitamin D receptor (VDR) in rheumatoid tissues. **(a)** Immunolocalization of VDR in rheumatoid synovium. Note positive red immunostaining of fibroblastic cells. (Counterstain Harris\'s haematoxylin; bar = 25 μm.) **(b)** Demonstration of VDR in cartilage from a rheumatoid joint. Note both positive and negative chondrocytes. (Counterstain Harris\'s haematoxylin; bar = 20 μm.) **(c)** VDR immunolocalization at the cartilage-pannus junction; cells within both pannus tissue and cartilage can be seen to be expressing the receptor. (Counterstain toluidine blue; bar = 25 μm.)](ar-1-1-063-1){#F1}

![The effects of 1α,25-hydroxyvitamin D~3~ (1,25) on matrix metalloproteinase (MMP)-1, MMP-3 and MMP-9 production by rheumatoid synovial fibroblasts (RSFs) after 48 h incubation. **(a)** MMP-1 production by RSFs (*n* = 3) showing normalized values for control; + 1,25 (10^-8^mol/l); + interleukin (IL)-1β (0.05 ng/ml); and + IL-1β and 1,25 (0.05 ng/ml and 10^-8^ mol/l, respectively). Before normalization, control values for MMP-1 were in the range 50--200 ng/ml culture medium/10^6^ cells per 48 h. **(b)** MMP-3 production by RSF (*n* = 3) showing normalized values for control; + 1,25; + IL-1β; and + IL-1β and 1,25. Before normalization, control values for MMP-3 were in the range 10--40 ng/ml culture medium/10^6^ cells per 48 h. **(c)** MMP-9 production by RSFs (*n* = 3) showing normalized values for control; + 1,25; + IL-1β; and +IL-1β and 1,25. Before normalization, control values for MMP-9 were in the range 10-50 ng/ml culture medium/10^6^ cells per 48 h. Values are shown as means ± SEM.](ar-1-1-063-2){#F2}

![The effects of 1α,25-hydroxyvitamin D^3^ (1,25) on matrix metalloproteinase (MMP)-1 and MMP-3 production by human articular chondrocytes (HACs) after 48 h incubation. **(a)** MMP-1 production by HAC (*n* = 3) showing normalized data for control; + 1,25 (10^-8^mol/l); + interleukin (IL)-1β (0.05 ng/ml); and + IL-1β and 1,25 (0.05 ng/ml and 10^-8^ mol/l, respectively). Before normalization, control values for MMP-1 were in the range 50--150 ng/ml culture medium/10^6^ cells per 48 h. **(b)** MMP-3 production by HAC (*n* = 3) showing normalized data for control; +1,25; + IL-1β; and + IL-1β and 1,25. Before normalization, control values for MMP-3 were in the range 10--40 ng/ml culture medium/10^6^ cells per 48 h. Values are shown as means ± SEM.](ar-1-1-063-3){#F3}

![The effects of 1α,25-hydroxyvitamin D~3~ (1,25) on prostaglandin E~2~ (PGE~2~) production by rheumatoid synovial fibroblasts (RSFs) and human articular chondrocytes (HACs) after 48 h incubation. **(a)**PGE~2~production by RSFs (*n* = 3) showing normalized data for control; + 1,25 (10^-8^ mol/l); + interleukin (IL)-1β (0.05 ng/ml); and + IL-1β and 1,25 (0.05 ng/ml and 10^-8^ mol/l, respectively). Before normalization, control values for PGE~2~ production by RSFs were in the range 500--2000 pg/ml culture medium/10^6^ cells per 48 h. **(b)**PGE~2~ production by HACs (*n* = 3) showing normalized data for control; + 1,25; + IL-1β; and + IL-1β and 1,25. Before normalization control values for PGE~2~ production by HAC were in the range 100--300 pg/ml culture medium/10^6^ cells per 48 h. **(c)** Normalized data for PGE~2~production by IL-1β-stimulated RSFs after preincubation with 1α,25(OH)~2~D~3~, as follows: A, control; B, +IL-1β; C, 1,25 + IL-1β; D, 1 h preincubation with 1,25, then + IL-1β and 1,25; E, 16 h preincubation with 1,25, then IL-1β + 1,25; F, 16 h preincubation with 1,25, then IL-1β alone. Values are shown as means ± SEM.](ar-1-1-063-4){#F4}

Discussion
==========

The cell types within the rheumatoid lesion which were observed to express VDR included chondrocytes, fibroblasts, macrophages, lymphocytes and endothelial cells. These cells are all purported to be involved either directly or indirectly in the degradative processes associated with rheumatoid arthritis, possibly via their MMP and prostanoid production, or via the production of mediators responsible for inflammation and induction of proteinase expression by other cell types. Thus, the demonstration of VDR within the rheumatoid lesion provides support for a functional role of 1α,25(OH)~2~D~3~ in rheumatoid arthritis.

MMPs are considered to play important roles in the chondrolytic processes of the rheumatoid lesion \[[@B14],[@B15],[@B17]\]. These enzymes are known to be produced by both fibroblasts and chondrocytes, but little has been reported in the literature regarding a relationship between 1α,25(OH)~2~D~3~and MMP production or its regulation, and most of the data to date have been obtained from animal studies or immortalized cell lines \[[@B5],[@B6],[@B7]\]. 1α,25(OH)~2~D~3~ had little effect on basal MMP production by RSFs and marginally increased the basal production of MMP-1 and MMP-3 by chondrocytes. More pronounced differences were noted when IL-1β-stimulated or activated cells were treated with 1α,25(OH)~2~D~3~, the RSFs and HACs showing quite disparate responses. These opposite effects may be of relevance to the processes of joint destruction, especially cartilage loss, because the ability of 1α,25(OH)~2~D~3~to potentiate MMP-1 and MMP-3 expression by \'activated\' chondrocytes might facilitate intrinsic cartilage chondrolysis *in vivo*. By contrast, the MMP-suppressive effects observed for 1α,25(OH)~2~D~3~ treatment of \'activated\' synovial fibroblasts might reduce extrinsic chondrolysis and also matrix degradation within the synovial tissue. We recognize that the present study is somewhat restricted to the 1α,25(OH)~2~D~3~ effects on MMP-1 and MMP-3 production. Although these are prominent and well characterized MMPs, there are many other enzymes in this family, together with plasminogen activators and other proteinases, which have not been examined. From the disparate effects of 1α,25(OH)~2~D~3~ on the RSFs and HACs it would seem that further studies on the 1α,25(OH)~2~D~3~-modified proteinase phenotypes of these cells are warranted.

Prostaglandins are primary mediators of inflammation and have important roles in the immune response and the inflammatory processes associated with rheumatoid arthritis, and PGE~2~ has been implicated in the potentiation of MMP production by some cell cultures \[[@B22],[@B23]\]. 1α,25(OH)~2~D~3~ had little effect on basal PGE~2~ production by RSFs, but the enhanced PGE~2~ production observed following IL-1β stimulation of these cells was markedly suppressed by the concomitant addition of 1α,25(OH)~2~D~3~. By contrast, the increased PGE~2~ production observed for IL-1β-treated HACs was unaffected by the simultaneous addition of 1α,25(OH)~2~D~3.~ Thus, as with MMP production, 1α,25(OH)~2~D~3~ has disparate effects on IL-1β-stimulated PGE~2~ production by these two cell types. Different responses by RSFs and HACs to the same ligand have been noted before; for example, IL-1β treatment was shown to stimulate glycosaminoglycan synthesis by RSFs, but inhibited its production by chondrocytes \[[@B24]\].

In summary, the immunolocalization of VDR in the rheumatoid lesion has demonstrated that the metabolite 1α,25(OH)~2~D~3~might have a functional role in the degradative and inflammatory processes of joint disease. Whereas 1α,25(OH)~2~D~3~ does not appear directly to affect the MMP or prostanoid production by unstimulated RSFs or HACs *in vitro*, it was shown to modulate the cytokine-induced MMP and PGE~2~ production by these two cell cultures. The recognized immunomodulatory properties of 1α,25(OH)~2~D~3~ could well be important in rheumatoid tissues, in which the inflammatory response is a characteristic feature. The transient, local manifestations of cartilage and matrix-degrading activity \[[@B25]\] could be modified by 1α,25(OH)~2~D~3~ if the cells present express VDR and the metabolite is produced locally. This study has demonstrated that most rheumatoid synovial specimens were expressing VDR at the time of surgery, and that IL-1β-\'activated\' synovial fibroblasts and chondrocytes *in vitro* showed significant and different responses to 1α,25(OH)~2~D~3~ exposure with regard to MMP and PGE~2~ production. Such observations suggest that 1α,25(OH)~2~D~3~ contributes indirectly rather than directly to MMP regulation via its action on other mediators or their signalling pathways, in accord with its recognized multifunctional and immunomodulatory properties \[[@B1],[@B7]\].
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